临床肿瘤学杂志

• 论著 • 上一篇    下一篇

CD4+/CD25+与CD28+/TCR+T淋巴细胞亚群与进展期鼻咽癌患者预后的关系

李永强,刘志辉,胡晓桦,林燕,廖小莉,梁嵘,原春玲,廖思娜   

  1. 广西医科大学附属肿瘤医院化疗一科
  • 收稿日期:2013-07-22 修回日期:2013-09-06 出版日期:2013-12-31 发布日期:2013-12-31
  • 通讯作者: 刘志辉

The relationship of CD4+/CD25+ and CD28+/TCR+T cells with the prognosis in patients with advanced nasopharyngeal carcinoma

LI Yongqiang, LIU Zhihui, HU Xiaohua, LIN Yan, LIAO Xiaoli, LIANG Rong, YUAN Chunling, LIAO Sina.   

  1. Department of First Chemotherapy, Affiliated Cancer Hospital of Guangxi Medical University
  • Received:2013-07-22 Revised:2013-09-06 Online:2013-12-31 Published:2013-12-31
  • Contact: LIU Zhihui

摘要: 目的 探讨外周血CD4+/CD25+与CD28+/TCR+T淋巴细胞亚群对预测进展期鼻咽癌患者预后的潜在价值。方法 收集本院2011年4月至2011年10月收治的53例进展期鼻咽癌患者(鼻咽癌组)的外周静脉血样本,应用葡聚糖泛影葡胺密度梯度离心法收集淋巴细胞并用流式细胞仪检测CD4+/CD25+与CD28+/TCR+T淋巴细胞亚群的百分比。根据联合放化疗后随访18个月的结果分析CD4+/CD25+与CD28+/TCR+T细胞亚群水平与鼻咽癌复发的关系。同时选取29例健康志愿者作对照(对照组)。结果 鼻咽癌组的外周血CD4+/CD25+和CD28+/TCR+T淋巴亚群占总淋巴细胞的百分率为(10.6±2.7)%和(1.9±0.6)%,与对照组的(7.7±2.0)%和(2.9±1.0)%相比,差异均有统计学意义(P<0.05)。参照对照组外周血CD4+/CD25+和CD28+/TCR+T淋巴亚群占总淋巴细胞百分率的95%置信区间分别为(6.9~8.5)%和(2.5~3.2)%,将鼻咽癌组的CD4+/CD25+T细胞分为正常组(≤8.5%)和升高组(>8.5%),CD28+/TCR+T细胞分为正常组(≥2.5%)和降低组(<2.5%)。鼻咽癌外周血CD4+/CD25+T细胞升高组在治疗后18月内的复发率为32.1%,明显高于正常组的8.7%(P<0.05);CD28+/TCR+T细胞降低组和正常组的复发率分别为23.3%和19.0%,差异无统计学意义(P>0.05)。
结论CD4+/CD25+T淋巴细胞亚群是潜在的可评价进展期鼻咽癌患者复发风险的预测因子。

Abstract: Objective To compare the differences of the proportions of CD4+/CD25+and CD28+/TCR+T cells in peripheral blood between patients with advanced nasopharyngeal carcinoma(NPC) and healthy volunteers, and explore the potential significance of the aberrant lymphocyte subpopulations of T cells for prognosis in NPC patients. Methods Twenty-nine healthy volunteers(control group) and 53 patients with advanced NPC(NPC group) were recruited. The peripheral venous blood samples were harvested and the peripheral lymphocytes were isolated and collected by ficollhypaque density centrifugation. The proportions of CD4+/CD25+ and CD28+/TCR+T cells were measured by flow cytometry. The relationship between the aberrant proportions of these T cells and the risk of relapse in NPC patients was analyzed according to the followup data of 18 months after chemoradiotherapy. Results The proportion of CD4+/CD25+T cells in NPC group was(10.6±2.7)%, higher than(7.7±2.0)% in control group(P<0.05), whereas the proportion of CD28+/TCR+T cells in NPC group was(1.9±0.6)%, lower than(2.9±1.0)% in control group(P<0.05). According to the 95% confidence interval of the proportions of CD4+/CD25+and CD28+/TCR+T cells in control group, the NPC group was divided into normal(≤8.5%) and elevated(>8.5%) CD4+/CD25+T subgroup or normal(≥2.5%) and reduced(<2.5%) CD28+/TCR+T subgroup. The relapse rate of elevated CD4+/CD25+T subgroup within 18 months after treatment was 32.1%, higher than 87% of normal subgroup with significant difference(P<005). No difference was observed between subgroups of CD28+/TCR+T. Conclusion The proportion of CD4+/CD25+T cells is a potential prognostic factor for the risk of relapse in patients with advanced NPC.

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!